Abstract
Lipid rafts are membrane microdomains particularly enriched in cholesterol, sphingolipids and saturated fatty acids. These microstructures play a key role in a plethora of mechanisms involved in cell signaling, synapsis, cell-cell communication and cell survival. In the last years, increasing evidence indicate that lipid rafts may be altered in age-related neuropathologies, such as Alzheimer’s disease and Parkinson disease even at asymptomatic stages. In particular, important changes in raft lipid composition are observed with the progression of these diseases, then inducing alterations in their physicochemical properties. Furthermore, these phenomena contribute to neuropathological events related to amyloidogenesis, aberrant protein aggregation and toxic cell signalling. In this review, we discuss some relevant data on the age-related molecular changes occurring in lipid rafts since the first stages of these neurodegenerative diseases. Further characterization of specific parameters associated with alterations of these microdomains may provide potential tools of diagnosis and prediction of these neuropathologies.
Keywords: Alzheimer’s disease, biomarkers, cerebrospinal fluid, lipid rafts, lipids, Parkinson disease, signalosomes.
Current Alzheimer Research
Title:Lipid Raft Alterations in Aged-Associated Neuropathologies
Volume: 13 Issue: 9
Author(s): Raquel Marin, Noemí Fabelo, Cecilia Fernández-Echevarría, Ana Canerina-Amaro, Deiene Rodríguez-Barreto, David Quinto-Alemany, Fátima Mesa-Herrera and Mario Díaz
Affiliation:
Keywords: Alzheimer’s disease, biomarkers, cerebrospinal fluid, lipid rafts, lipids, Parkinson disease, signalosomes.
Abstract: Lipid rafts are membrane microdomains particularly enriched in cholesterol, sphingolipids and saturated fatty acids. These microstructures play a key role in a plethora of mechanisms involved in cell signaling, synapsis, cell-cell communication and cell survival. In the last years, increasing evidence indicate that lipid rafts may be altered in age-related neuropathologies, such as Alzheimer’s disease and Parkinson disease even at asymptomatic stages. In particular, important changes in raft lipid composition are observed with the progression of these diseases, then inducing alterations in their physicochemical properties. Furthermore, these phenomena contribute to neuropathological events related to amyloidogenesis, aberrant protein aggregation and toxic cell signalling. In this review, we discuss some relevant data on the age-related molecular changes occurring in lipid rafts since the first stages of these neurodegenerative diseases. Further characterization of specific parameters associated with alterations of these microdomains may provide potential tools of diagnosis and prediction of these neuropathologies.
Export Options
About this article
Cite this article as:
Marin Raquel, Fabelo Noemí, Fernández-Echevarría Cecilia, Canerina-Amaro Ana, Rodríguez-Barreto Deiene, Quinto-Alemany David, Mesa-Herrera Fátima and Díaz Mario, Lipid Raft Alterations in Aged-Associated Neuropathologies, Current Alzheimer Research 2016; 13 (9) . https://dx.doi.org/10.2174/1567205013666160314150017
DOI https://dx.doi.org/10.2174/1567205013666160314150017 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science The Neuroprotective Effects of Purslane (Portulaca oleracea) on Rotenone- Induced Biochemical Changes and Apoptosis in Brain of Rat
CNS & Neurological Disorders - Drug Targets Preface [Hot topic: Protein Crystallography in Drug Design (Guest Editor: Jonathan B. Cooper)]
Current Drug Targets Modern Computational Strategies for Designing Drugs to Curb Human Diseases: A Prospect
Current Topics in Medicinal Chemistry Gastroesophageal Reflux Disease (GERD): Current Agents and Future Perspective
Current Pharmaceutical Design Patent Review on Network-based Elderly Healthcare System in the US
Recent Patents on Computer Science Current Status and Recent Developments in Anthracenone Antipsoriatics
Current Pharmaceutical Design ICP-MS: Analytical Method for Identification and Detection of Elemental Impurities
Current Drug Discovery Technologies Mucopolysaccharidosis Type IVA (Morquio A Disease): Clinical Review and Current Treatment: A Special Review
Current Pharmaceutical Biotechnology Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Challenges in Neuronal Apoptosis
Current Alzheimer Research Septomics: Application of Systems Approaches to Sepsis - Potential for Personalized Management of Septic Patients
Current Pharmacogenomics and Personalized Medicine Development and In Vitro Evaluation of Ketoprofen Extended Release Pellets Using Powder Layering Technique in a Rotary Centrifugal Granulator
Combinatorial Chemistry & High Throughput Screening The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design The Medicinal Chemistry of Peptides
Current Medicinal Chemistry On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Adsorption and Bioactivity of Tyrosine Hydroxylase on Gold Surfaces and Nanoparticles
Protein & Peptide Letters Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets